Chandra Bhagat Pharma share price
BSE: 542934Pharmaceuticals & BiotechnologySmall Cap
Last close ₹39.00down ₹1.00 (2.50%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹40.00.
52-week range of traded prices to 23 Oct 2026
₹29.70Low, 6 May 2026₹52.99High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹29 Cr3,869th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 25 May 2026
- 10.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 25 May 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 25 May 2026
- 9.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 25 May 2026
- 0.50
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,000
Results
Standalone; ₹ crore, the charts by years to March, the table by half year.Half-yearly results
Half year to Mar 2026, against the half year beforeFiled 25 May
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹91 Crup 255.15%
- Net profitNet profit. The pill is the change in net profit against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹2.60 Crup 1,035.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 2.9%
Revenue by year
Peak revenue ₹221 Cr, year to Mar 2024
Net profit by year, a loss in red
| ₹ crore | Sep 2022Filed 25 Nov | Mar 2023Filed 23 May | Sep 2023Filed 2 Dec | Mar 2024Filed 8 Aug | Sep 2024Filed 25 Nov | Mar 2025Filed 29 May | Sep 2025Filed 13 Nov | Mar 2026Filed 25 May |
|---|---|---|---|---|---|---|---|---|
| Revenue | 44 | 75 | 119 | 102 | 65 | 22 | 26 | 91 |
| Net profit | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 0.8% | 0.7% | 0.5% | 0.9% | 1.1% | 0.8% | 0.9% | 2.9% |
Standalone. The last eight half years. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMA, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −41.7% | +254.4% | −83.6% | 0.0% |
| 3 years | −32.0% | +49.9% | −54.6% | 0.0% |
| 5 years | −5.1% | +74.5% | −45.6% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Chandra Bhagat Pharma in market cap. 1 company in the table last traded before then: its row is priced on its last trade.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Roopa IndustriesROOPAIND | 34 | 269.3 | 2.0 | 7.7 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Jfl Life SciencesJFLLIFE | 34 | 5.0 | 0.7 | 4.6 | – | – | 15.9% | 15.9% | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 33 | 18.5 | 0.8 | 8.8 | +4.2% | +10.3% | 4.1% | 5.3% | 2.94% |
 Medi CapsMEDICAPQ | 31 | – | 0.3 | – | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.0 | 2.0 | – | – | – | 28.9% | – | 0.00% |
 Sunrest LifescienceSUNREST | 29 | 7.0 | – | – | – | – | 22.4% | – | 0.00% |
 Bacil PharmaBACPHAR | 29 | – | 1.1 | – | – | – | – | −0.7% | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 27 | 12.7 | 2.7 | 7.6 | −7.2% | – | 25.8% | 25.8% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Announcement under Regulation 30 (LODR)-Allotment
21 Oct · Certificate For Non-Applicability Of Corporate Governance For The Quarter Ended 30Th September, 2026.
13 Oct · Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015 For Receipt Of BSE IP Approval
Sep 2026
Chandra Bhagat Pharma share price by year
Each calendar year to 2025.Chandra Bhagat Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 41.25 | −37.2% | 70.99 | 35.00 |
| 2024 | 65.67 | −43.9% | 147.50 | 63.10 |
| 2023 | 117.05 | +3.6% | 154.35 | 90.25 |
| 2022 | 113.00 | +25.6% | 138.00 | 77.25 |
| 2021 | 90.00 | +100.0% | 147.50 | 38.25 |
| 2020 | 45.00 | – | 53.05 | 31.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 14 Feb 2020.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 39.00 | 39.00 | 39.00 | 39.00 | 39.00 | 2,000 |
| 19 Oct 2026 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 2,000 |
| 16 Oct 2026 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 2,000 |
| 13 Oct 2026 | 35.02 | 41.80 | 35.02 | 41.80 | 37.28 | 3,000 |
| 8 Oct 2026 | 42.00 | 42.00 | 38.14 | 38.20 | 41.65 | 66,000 |
| 7 Oct 2026 | 42.37 | 42.37 | 42.37 | 42.37 | 42.37 | 8,000 |
| 6 Oct 2026 | 44.59 | 44.59 | 44.59 | 44.59 | 44.59 | 4,000 |
| 5 Oct 2026 | 46.93 | 46.93 | 46.93 | 46.93 | 46.93 | 1,000 |
| 28 Sep 2026 | 49.40 | 49.40 | 49.40 | 49.40 | 49.40 | 1,000 |
| 22 Sep 2026 | 52.00 | 52.99 | 49.45 | 49.45 | 50.98 | 6,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Chandra Bhagat Pharma Limited
- BSE code
- 542934
- ISIN
- INE07QQ01016
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Feb 2020
- Face value
- ₹10
- CIN
- L24230MH2003PLC139534
- Corporate identity number, the registrar of companies' code for it